Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy

Complementary Therapies in Medicine

Volumn 21, Issue 6, 2013, Pages 712-723

  Mego, Michal ^a   Holec, Vladimir ^b   Drgona, Lubos ^a   Hainova, Katarina ^a   Ciernikova, Sona ^a   Zajac, Vladimir ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b SLOVAK MEDICAL UNIVERSITY   (Slovakia)

Author keywords

Cancer; Chemotherapy; Probiotics; Radiation therapy

Indexed keywords

ANTIBIOTIC AGENT; COTRIMOXAZOLE; FLUOROURACIL; FOLINIC ACID; FRAMYCETIN; METRONIDAZOLE; NEOMYCIN; NYSTATIN; PROBIOTIC AGENT;

ADJUVANT THERAPY; ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL INFECTION; BACTERIAL SURVIVAL; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HUMAN; INFECTION PREVENTION; INFECTION SENSITIVITY; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS BREVIS; LACTOBACILLUS CASEI; LACTOBACILLUS RHAMNOSUS; LACTOSE INTOLERANCE; LEUKEMIA; MUCOSA INFLAMMATION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR;

CANCER; CHEMOTHERAPY; PROBIOTICS; RADIATION THERAPY;

BACTERIAL INFECTIONS; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PROBIOTICS;

EID: 84888021129     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2013.08.018     Document Type: Review

References (88)

1. Richardson M.A., Sanders T., Palmer J.L., et al. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 2000, 18:2505-2514.
2. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989, 66:365-378.
3. Girardin M., Seidman E.G. Indications for the use of probiotics in gastrointestinal diseases. Dig Dis 2011, 29:574-587.
4. Goldin B.R., Gorbach S.L. Clinical indications for probiotics: an overview. Clin Infect Dis 2008, 46:S96-S100.
5. Ferencík M., Ebringer L., Mikes Z., Jahnová E., Ciznár I. Successful modification of human intestinal microflora with oral administration of lactic acid bacteria. Bratisl Lek Listy 1999, 100:238-245.
6. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 2006, 83:1256-1264.
7. Fotiadis C.I., Stoidis C.N., Spyropoulos B.G., Zografos E.D. Role of probiotics, prebiotics and synbiotics in chemoprevention for colorectal cancer. World J Gastroenterol 2008, 14:6453-6457.
8. Fuccio L., Guido A., Eusebi L.H., et al. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. J Clin Gastroenterol 2009, 43:506-513.
9. Mego M., Ebringer L., Koza I., et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Pilot study phase I. Neoplasma 2005, 52:159-164.
10. Mego M., Koncekova R., Mikuskova E., et al. Prevention of febrile neutropenia in cancer patients by probiotic strain Enterococcus faecium M-74. Phase II study. Support Care Cancer 2006, 14:285-290.
11. Klastersky J. A review of chemoprophylaxis and therapy of bacterial infections in neutropenic patients. Diagn Microbiol Infect Dis 1989, 12(Suppl 4):201S-207S.
12. Marshall J.C. Gastrointestinal flora and its alterations in critical illness. Curr Opin Clin Nutr Metab Care 1999, 2:405-411.
13. Glauser M.P., Calandra T. Infections in patients with hematologic malignancies. Management of infections in immunocompromised patients 2000, 141-188. W.B. Saunders, St. Louis, MO. M.P. Glauser, P.A. Pizzo (Eds.).
14. Schimpff S.C., Young V.M., Green W.H. Origin of infection in acute lymphocytic leukemia: significance of hospital aquisition of potential pathogens. Ann Intern Med 1972, 77:707-714.
15. Buck A.C., Cooke E.M. The fate of ingested Pseudomonas aeruginosa in normal persons. J Med Microbiol 1969, 2:521-525.
16. Marin M.L., Tejada-Simon M.V., Lee J.H., Murtha J., Ustunol Z., Pestka J.J. Stimulation of cytokine production in clonal macrophage and T-cell models by Streptococcus thermophilus: comparison with Bifidobacterium sp. and Lactobacillus bulgaricus. J Food Prot 1998, 61:859-864.
17. Zoetendal E.G., Akkermans A.D., De Vos W.M. Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. Appl Environ Microbiol 1998, 64:3854-3859.
18. Engels A.E., Lau J., Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998, 16:1179-1187.
19. Nauseef W.M., Maki D.G. A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 1981, 304:448-453.
20. Neumann E., Oliveira M.A., Cabral C.M., et al. Monoassociation with Lactobacillus acidophilus UFV-H2b20 stimulates the immune defense mechanisms of germ free mice. Braz J Med Biol Res 1998, 31:1565-1573.
21. Perdigon G., Alvarez S., Rachid M., Aguero G., Gobbato N. Immune system stimulation by probiotics. J Dairy Sci 1995, 78:1597-1606.
22. Resta-Lenert S., Barrett K.E. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherischia coli (EIEC). Gut 2003, 52:988-997.
23. Vandenplas Y. Bacteria and yeast in the treatment of acute and chronic infectious diarrhea. Part I. Bacteria. Clin Microbiol Infect 1999, 5:299-307.
24. Hasegawa T., Kanasugu H., Hidaka M., Yamamoto T., Abe S., Yamaguchi H. Effect of orally administered heat-killed Enterococcus faecalis FK-23 preparation on neutropenia in dogs treated with cyclophosphamide. Int Immunopharmacol 1996, 18:103-112.
25. Baba E., Nagaishi M., Fukata T., Arakawa A. The role of intestinal microflora on the prevention of Salmonella colonization in gnotobiotic chickens. Poult Sci 1991, 70:1902-1907.
26. Taguchi H., Takahashi M., Yamaguchi H., et al. Experimental infection of germ-free mice with hyper-toxigenic enterohemorrhagic Escherischia coli O157:H7, strain 6. J Med Microbiol 2002, 51:336-343.
27. Satonaka K., Ohashi K., Nohmi T., et al. Prophylactic effect of Enterococcus faecalis FK-23 preparation on experimental candidiasis in mice. Microbiol Immunol 1996, 40:217-222.
28. Hengens C., Klastersky J. Intestinal colonization with lactobacilli strains in neutropenic patients. Biomedicine 1976, 25:11-15.
29. Ekerk H., Jurk I.H., Waters K.D., Tiedemann K. Prophylactic co-trimoxazole and lactobacilli preparation in neutropenic patients. Med Pediatr Oncol 1980, 8:47-51.
30. Wada M., Nagata S., Saito M., et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 2010, 18:751-759.
31. Asahara T., Nomoto K., Shimizu K., Watanuki M., Tanaka R. Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides. J Appl Microbiol 2001, 91:985-996.
32. Asahara T., Shimizu K., Nomoto K., Hamabata T., Ozawa A., Takeda Y. Probiotic Bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 2004, 72:2240-2247.
33. Michael M., Brittain M.A., Nagai J., et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol 2004, 22:4410-4417.
34. Bowen J.M., Stringer A.M., Gibson R.J., et al. VSL no. 3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007, 6:1449-1454.
35. Whitford E.J., Cummins A.G., Butler R.N., et al. Effects of Streptococcus thermophilus TH-4 on intestinal mucositis induced by the chemotherapeutic agent, 5-Fluorouracil (5-FU). Cancer Biol Ther 2009, 8:505-511.
36. Gafter-Gvili A., Fraser A., Paul M., Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005, 142:979-995.
37. Born P., Lersch C., Zimmerhackl B., Classen M. The Saccharomyces boulardii therapy of HIV-associated diarrhea. Dtsch Med Wochenschr 1993, 118:765.
38. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006, 101:812-822.
39. Kale-Pradhan P.B., Jassal H.K., Wilhelm S.M. Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis. Pharmacotherapy 2010, 30:119-126.
40. Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012, 307:1959-1969.
41. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev 2011 Nov 9, (11). CD004827.
42. D'Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002, 324:1361-1366.
43. Wiernik P.H., Bansks P.L.C., Case D.C., et al. Cytarabine plus idarubicine or daunorubicine as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992, 79:313-319.
44. Camera A., Andretta C., Villa M.R., et al. Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol J 2003, 4:346-350.
45. Osterlund P., Ruotsalainen T., Peuhkuri K., et al. Lactose intolerance associated with adjuvant 5-fluorouracil-based chemotherapy for colorectal cancer. Clin Gastroenterol Hepatol 2004, 2:696-703.
46. Osterlund P., Ruotsalainen T., Korpela R., et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007, 97:1028-1034.
47. Ludgate S.M., Merrick M.V. The pathogenesis of post-irradiation chronic diarrhoea: measurement of SeHCAT and B12 absorption for differential diagnosis determines treatment. Clin Radiol 1985, 36:275-278.
48. Gami B., Harrington K., Blake P., et al. How patients manage gastrointestinal symptoms after pelvic radiotherapy. Aliment Pharmacol Ther 2003, 18:987-994.
49. Andreyev H.J., Vlavianos P., Blake P., et al. Gastrointestinal symptoms after pelvic radiotherapy: role for the gastroenterologist. Int J Radiat Oncol Biol Phys 2005, 62:1464-1471.
50. Crawford P.A., Gordon J.I. Microbial regulation of intestinal radiosensitivity. PNAS 2005, 102:13254-13259.
51. Husebye E., Skar V., Hoverstad T., et al. Abnormal intestinal motor patterns explain enteric colonization with Gram-negative bacilli in late radiation enteropathy. Gastroenterology 1995, 109:1078-1089.
52. Summers R.W., Glenn C.E., Flatt A.J., et al. Radiation and indomethacin effects on morphology, prostaglandins, and motility in dog jejunum. Am J Physiol 1991, 261:G145-G151.
53. Danielsson A., Nyhlin H., Persson H., et al. Chronic diarrhea after radiotherapy for gynaecological cancer: occurrence and aetiology. Gut 1991, 32:1180-1187.
54. Berg R.D. Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol 1999, 473:11-30.
55. Demirer S., Aydintug S., Aslim B., et al. Effects of probiotics on radiation-induced intestinal injury in rats. Nutrition 2006, 22:179-186.
56. Seal M., Naito Y., Barreto R., et al. Experimental radiotherapy induced enteritis: a probiotic interventional study. J Dig Dis 2007, 8:143-147.
57. Ciorba M.A., Riehl T.E., Rao M.S., et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 2012, 61:829-838.
58. Salminen E., Elomaa I., Minkkinen J., et al. Preservation of intestinal integrity during radiotherapy using live Lactobacillus acidophilus cultures. Clin Radiol 1988, 39:435-437.
59. Delia P., Sansotta G., Donato V., et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007, 13:912-915.
60. Giralt J., Regadera J.P., Verges R., et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiationinduced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008, 71:1213-1219.
61. Abd El-Atti S., Wasicek K., Mark S., Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN: J Parenter Enteral Nutr 2009, 33:569-570.
62. Urbancsek H., Kazar T., Mezes I., et al. Results of a doubleblind, randomized study to evaluate the efficacy and safety of antibiophilus in patients with radiation-induced diarrhoea. Eur J Gastroenterol Hepatol 2001, 13:391-396.
63. Sharma A., Rath G.K., Chaudhary S.P., Thakar A., Mohanti B.K., Bahadur S. Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer 2012, 48:875-881.
64. Vanderhoof J.A., Young R. Probiotics in the United States. Clin Infect Dis 2008, 46:S67-S72.
65. Swenson J.M., Facklamand R.R., Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother 1990, 34(4):543-549.
66. Handwerger S., Pucci M.J., Volk K.J., Liu J.P., Lee M.S. Vancomycin-resistant Leuconostoc mesenteroides and Lactobacillus casei synthesize cytoplasmic peptidoglycan precursors that terminate in lactate. J Bacteriol 1994, 176:260-264.
67. Klein G., Pack A., Bonaparte C., Reuter G. Taxonomy and physiology of probiotic lactic acid bacteria. Int J Food Microbiol 1998, 41:103-105.
68. Charteris W.P., Kelly P.M., Morelli L., Collins J.K. Antibiotic susceptibility of potentially probiotic Lactobacillus species. J Food Prot 1998, 61:1636-1643.
69. Salminen S., von Wright A., Morelli L., et al. Demonstration of safety of probiotics-a review. Int J Food Microbiol 1998, 44:93-106.
70. Tynkkynen S., Singh K.V., Varmanen P. Vancomycin resistance factor of Lactobacillus rhamnosus GG in relation to enterococcal vancomycin resistance (van) genes. Int J Food Microbiol 1998, 41:195-204.
71. Ahn C., Thompson D.C., Duncan C., Stiles M.E. Mobilization and location of the genetic determinant of chloramphenicol resistance from Lactobacillus plantarum ca TC2R. Plasmid 1992, 27:169-176.
72. Gevers D., Danielsen M., Huys G., Swings J. Molecular characterization of tet(M) genes in Lactobacillus isolates from different types of fermented dry sausage. Appl Environ Microbiol 2003, 69:1270-1275.
73. Ishiwa H., Iwata S. Drug resistance plasmids in Lactobacillus fermetum. J Gen Appl Microbiol 1980, 26:71-74.
74. Fons M., Hege T., Ladire M., Raibaud P., Ducluzeau R., Maguin E. Isolation and characterization of a plasmid from Lactobacillus fermentum conferring erythromycin resistance. Plasmid 1997, 37:199-203.
75. Tannock G.W., Luchansky J.B., Miller L., et al. Molecular characterization of a plasmid-borne (pGT633) erythromycin resistance determinant (ermGT) from Lactobacillus reuteri 100-63. Plasmid 1994, 31:60-71.
76. Morelli L., Wright A.V. Probiotic bacteria and transferable antibiotic resistance-safety aspects. Demonstration of the Nutritional Functionality of Probiotic Foods News Letter 1997, 2:9-14.
77. Saarela M., Mogensen G., Fonden R., Matto J., Mattila-Sandholm T. Probiotic bacteria: safety, functional and technological properties. J Biotechnol 2000, 84:197-215.
78. Salyers A.A., Gupta A., Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol 2004, 12:412-416.
79. Mathur S., Singh R. Antibiotic resistance in food lactic acid bacteria-a review. Int J Food Microbiol 2005, 105:281-295.
80. Gasser S. Safety of lactic acid bacteria and their occurrence in human clinical infection. Bull Inst Pasteur 1994, 92:45-67.
81. Berg R.D. Bacterial translocation from the gastrointestinal tract. Trends Microbiol 1995, 3:149-154.
82. Berg R.D. Translocation and the indigenous gut flora. Probiotics: the scientific basis 1992, 55-85. Chapman & Hall, London. R. Fuller (Ed.).
83. Fruchart C., Salah A., Gray C., et al. Lactobacillus species as emerging pathogens in neutropenic patients. Eur Clin Microbiol Infect Dis 1997, 16:681-684.
84. Olano A., Chua J., Schroeder S., Minari A., La Salvia M., Hall G. Weissella confusa (Basonym: Lactobacillus confusus) bacteremia: a case report. J Clin Microbiol 2001, 39:1604-1607.
85. Richard V., Van Der Auwera P., Snoeck R., Daneau D., Meunier F. Nosocomial bacteriemia caused by Bacillus species. Eur J Microbiol Infect Dis 1998, 7:783-785.
86. Cesaro S., Chinello P., Rossi L., Zanesco L. Saccharomyces cerevisiae fungemia in a neutropenic patient treated with Saccharomyces boulardii. Support Care Cancer 2000, 8:504-505.
87. Riquelme A.J., Calvo M.A., Guzman A.M., et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003, 36:41-43.
88. Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics to reduce risk and prevent or treat disease April 2011, Evidence Report/Technology Assessment no. 200, Agency for Healthcare Research and Quality, Rockville, MD, (Prepared by the Southern California Evidence-based Practice Center under Contract No. 290-2007-10062-I.) AHRQ Publication No. 11-E007. Available at: www.ahrq.gov/clinic/tp/probiotictp.htm.